Published in Pharma Law Weekly, December 29th, 2009
"RSCH significantly decreased the tumor weight by 44% and 53% in the 100 and 150 mg/kg/d groups, respectively, without causing mortality or growth retardation. The thymus and spleen indices (organ weight relative to body weight) were increased significantly in the 150 mg/kg/d group. The phagocytic capability of coeliac...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.